FENOFLOX 100 MG/ML SOLUTION FOR INJECTION FOR CATTLE AND PIGS
Страна: Ирландия
Язык: английский
Источник: HPRA (Health Products Regulatory Authority)
Характеристики продукта
(SPC)
15-09-2015
Некоторые документы для этого продукта в настоящее время недоступны, вы можете отправить запрос в нашу службу поддержки, и мы сообщим вам, как только мы сможем их получить.
Послать запрос.
Послать запрос.
Активный ингредиент:
ENROFLOXACIN
Доступна с:
Chanelle Pharmaceuticals Manufacturing Limited
код АТС:
QJ01MA90
ИНН (Международная Имя):
ENROFLOXACIN
дозировка:
100 Mg/Ml
Фармацевтическая форма:
Solution for Injection
Тип рецепта:
POM
Терапевтическая группа:
Bovine, Porcine
Терапевтические области:
Enrofloxacin
Терапевтические показания :
Antibacterial
Статус Авторизация:
Authorised
Дата Авторизация:
2010-05-14
Характеристики продукта
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fenoflox 100 mg/ml Solution for Injection for Cattle and Pigs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
Clear light yellow solution free from particulate matter.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and Pigs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of bacterial infections caused by strains susceptible to enrofloxacin.
Cattle
Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of _Pasteurella multocida,_
_Mannheimia haemolytica _and _Mycoplasma _spp.
Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of _Escherichia coli_.
Treatment of septicaemia caused by enrofloxacin susceptible strains of _Escherichia coli_.
Treatment of acute mycoplasma-associated arthritis due to enrofloxacin susceptible strains of _Mycoplasma bovis _in
cattle less than 2 years old.
Pigs
Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of _Pasteurella multocida,_
_Mycoplasma _spp. and _Actinobacillus pleuropneumoniae_.
Treatment of infections of the urinary tract caused by enrofloxacin susceptible strains of _Escherichia coli_.
Treatment of post-partum dysgalactiae syndrome, PDS (MMA syndrome) caused by enrofloxacin susceptible strains of
_Escherichia coli _and _Klebsiella _spp.
Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of _Escherichia coli_.
Treatment of septicaemia caused by enrofloxacin susceptible strains of _Escherichia coli_.
Each ml contains:
ACTIVE SUBSTANCE:
Enrofloxacin
100 mg
EXCIPIENT:
n-butanol
30 mg
For the full list of excipients, see section 6.1.
HEALTH PRODUCTS REGULATORY AUTHORITY
_________________
Прочитать полный документ
